Product/Composition:- | Olaparib |
---|---|
Strength:- | 100 mg, 150 mg |
Form:- | Tablet |
Reference Brands:- | Lynparza® (US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Olaparib Tablets (brand: Lynparza®) are oral PARP inhibitors for ovarian, breast, pancreatic, and prostate cancers, especially in BRCA-mutated cases. Available in 100 mg and 150 mg, and approved in the US and EU, Olaparib offers a reliable, GMP-compliant oncology solution for global B2B pharmaceutical distribution.
Olaparib Tablets, sold under the brand name Lynparza®, are oral PARP inhibitors used in treating advanced ovarian, breast, pancreatic, and prostate cancers, especially in patients with BRCA mutations. Olaparib interferes with cancer cell DNA repair, enhancing cell death in tumors with deficient repair mechanisms. Available in 100 mg and 150 mg strengths, these tablets are approved in both the US and EU and manufactured under GMP-certified facilities. As a breakthrough targeted therapy, Olaparib is a valuable option for oncology-focused pharmaceutical partners seeking high-quality, globally compliant formulations for B2B supply in regulated markets.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications